LIFECORE BIOMEDICAL, INC. Current Income Tax Expense (Benefit)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Current Income Tax Expense (Benefit) of $182.00 thousand for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. current income tax expense (benefit) for fiscal 2025 was $162.00K, a 500.00% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. current income tax expense (benefit) for fiscal 2024 was $27.00K, a 50.00% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. current income tax expense (benefit) for fiscal 2023 was $54.00K, a 85.75% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. current income tax expense (benefit) for fiscal 2022 was $379.00K, a 311.96% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 7 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $182.00K 10-KT · filed 2026-03-16 | ||
| 2025-05-25 | $162.00K 10-KT · filed 2026-03-16 | ||
| 2024-05-26 | $27.00K 10-KT · filed 2026-03-16 | ||
| 2023-05-28 | $54.00K 10-K · filed 2024-08-26 | ||
| 2022-05-29 | $379.00K 10-K · filed 2024-08-26 | ||
| 2021-05-30 | $92.00K 10-K · filed 2024-03-20 | ||
| 2020-05-31 | -$7.63M 10-K/A · filed 2023-03-16 | -$7.74M 10-K · filed 2020-08-14 | |
| 2019-05-26 | $79.00K 10-K · filed 2021-07-29 | ||
| 2018-05-27 | -$2.71M 10-K · filed 2020-08-14 | ||
| 2017-05-28 | $1.51M 10-K · filed 2019-08-01 | $1.83M 10-K · filed 2017-08-11 | |
| 2016-05-29 | $2.07M 10-K · filed 2018-08-09 | $2.38M 10-K · filed 2016-08-01 | |
| 2015-05-31 | $3.59M 10-K/A · filed 2018-03-15 | ||
| 2014-05-25 | $5.00M 10-K · filed 2016-08-01 | ||
| 2013-05-26 | $2.85M 10-K · filed 2015-07-31 | ||
| 2012-05-27 | $4.07M 10-K · filed 2014-08-01 | ||
| 2011-05-29 | $1.06M 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |